Search Results - "Hosback, Sarah"

Neutralizing Antibody Sample Testing and Report Harmonization by Jani, Darshana, Gunsior, Michele, Marsden, Robin, Cowan, Kyra J., Irvin, Susan C., Hay, Laura Schild, Ward, Bethany, Armstrong, Luke, Azadeh, Mitra, Cao, Liching, Carmean, Rebecca, DelCarpini, Jason, Dholakiya, Sanjay L., Hays, Amanda, Hosback, Sarah, Hu, Zheng, Kulagina, Nadia, Kumar, Seema, Lai, Ching Ha, Lichtfuss, Marit, Liu, Hsing-Yin, Liu, Susana, Mozaffari, Reza, Pan, Luying, Pennucci, Jason, Poupart, Marie-Eve, Saini, Gurleen, Snoeck, Veerle, Storey, Kristine, Turner, Amy, Vainshtein, Inna, Verthelyi, Daniela, Wala, Iwona, Yang, Lili, Yang, Lin

“…Immunogenicity testing and characterization is an important part of understanding the immune response to administration of a protein therapeutic. Neutralizing…”
Get full text

Correction to: Neutralizing Antibody Sample Testing and Report Harmonization by Jani, Darshana, Gunsior, Michele, Marsden, Robin, Cowan, Kyra J., Irvin, Susan C., Hay, Laura Schild, Ward, Bethany, Armstrong, Luke, Azadeh, Mitra, Cao, Liching, Carmean, Rebecca, DelCarpini, Jason, Dholakiya, Sanjay L., Hays, Amanda, Hosback, Sarah, Hu, Zheng, Kulagina, Nadia, Kumar, Seema, Lai, Ching Ha, Lichtfuss, Marit, Liu, Hsing-Yin, Liu, Susana, Mozaffari, Reza, Pan, Luying, Pennucci, Jason, Poupart, Marie-Eve, Saini, Gurleen, Snoeck, Veerle, Storey, Kristine, Turner, Amy, Vainshtein, Inna, Verthelyi, Daniela, Wala, Iwona, Yang, Lili, Yang, Lin

Get full text

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse by Smith, B. Douglas, Roboz, Gail J., Walter, Roland B., Altman, Jessica K., Ferguson, Anna, Curcio, Tania J., Orlowski, Kaysey F., Garrett, Linda, Busfield, Samantha J, Barnden, Megan, Sedgmen, Brad, Ghosh, Souravi, Hosback, Sarah, Davis, Roslyn, Dyson, Allison, Dasen, Sue, DeWitte, Mark, Bensen-Kennedy, Debra M., Roberts, Andrew W.

“…Background: Most patients with acute myeloid leukemia (AML) die from relapsed disease, including those who attain complete remission (CR). Post-remission…”
Get full text

A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML by Roberts, Andrew W., He, Simon, Bradstock, Kenneth F, Hertzberg, Mark S, Durrant, Simon T S, Ritchie, David, Lewis, Ian D., Marlton, Paula, McLachlan, Andrew J, Yeadon, Trina M, Busfield, Samantha J, Barnden, Megan J, Davis, Roslyn, Hosback, Sarah, Mirosa, Danijela, Biondo, Mark, Bamford, Simone, DeWitte, Mark, Basser, Russell

“…CD123 (IL-3Rα) is a phenotypic marker of putative leukemic stem cells (LSC) in AML (Jordan, Leukemia 2000; 14:1777). We and others have found that CD34+38−…”
Get full text